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Abstract
Due to various biological factors, males and
females differ in their response to drug treatment.
However, there is still a lack of knowledge of the effects
resulting from sex-differences in the medical field,
primarily due to females' underrepresentation in
clinical studies. Considering severe diseases related to
the cardiovascular system, which are likely to be
perilous, counteracting this lack and emphasizing the
need for sex-dependent drug treatment is of high
importance. Thus, this research-in-progress paper aims
to strengthen the female perspective in drug
management by proposing design considerations on IS
regarding recommender systems in healthcare to
reinforce shared decision-making and person-centered
care. The resulting artifact presented will be a reference
architecture with a mobile application as the interface
to patients and healthcare professionals as well as a
data-driven backend to collect and process data on sex
specificity in the medical treatment of cardiovascular
diseases (CVD).

1. Introduction
Despite the increasing awareness that sex-related
differences between males and females need to be
considered in drug treatment (e.g., [1], [2]), there is a
persisting lack of knowledge on varying drug tolerance
based on the sex of the patient, especially for females
(e.g., [3][4]). Biological differences between males and
females lead to differences in the pharmacokinetics and
the pharmacodynamics, in the drug absorption, in the
drug distribution in tissues, in the metabolism or the
differing excretion via the kidney and intestine [3]. The
biological causes for these differences lie predominantly
in the unequal genetic constitution of males and females,
diverse body conditions - e.g., females tend to have a
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lower body mass index, a smaller size of organs and
more adipose tissue - and in the impact of sexual
hormones [5][3]. Additionally, several studies showed
that the adverse side effects of medical drug use are
more frequent for females than males [1]. Thus, there is
an obvious need for sex-dependent drug treatment.
However, females are still underrepresented in clinical
trials. Even in the field of animal testing drugs are
predominantly tested on male animals assuming that sex
differences play no role in the clinical effect [3]. In this
regard, Karlsson-Lind et al. (2017) show that
information on sex differences lacks for a variety of
available medications [1]. Also, Regitz-Zagrosek
(2004) depicts that males and females differ in their
willingness to participate in their treatment process
actively and women tend to take different amounts of
possibly interacting over-the-counter drugs for selfmedication in addition to prescribed drugs [3].
Especially for severe diseases such as CVDs, which
are the most relevant cause of mortality and morbidity
worldwide, sex-related cardiovascular risk-factors and
respective drug administration are essential
determinants of treatment success [5]. However, there is
a lack of knowledge for female-specific needs in
medical treatment, which accordingly can become
extremely dangerous [6].
All those factors emphasize the importance of
gaining fundamental knowledge on female-specific
needs in drug management, especially in CVD. Thus,
our study proposes design consideration for information
systems (IS) focusing on strengthening the female
perspective in drug administration, regarding aspects
such as female-specific side-effects and drug dosage and
potential drug interactions. Specifically, the focus is on
the decision-making process for the medical treatment
of CVD patients. With this, we aim to contribute design
knowledge on how to identify, communicate, and
handle female-specific CVD drug responses. While
female patients are our primary stakeholders, healthcare
professionals need to be considered and are the primary
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decision-makers in medical treatment. Also, as the sex
inequity in medical treatment arises from narrow
research, both from academia and the drug industry,
they are essential stakeholders to close the persisting
knowledge gap on sex-specificities in medical
treatment. Our study focuses on Germany as a target
country.
The paper is structured as follows: First, we
introduce core socio-technical and technical
foundations. Second, we review the literature to carve
out the knowledge gap and gain insights into the
solution space. Third, we introduce our general design
science research methodology. Fourth, we describe the
first iteration of our proposed IS artifact and the first
evaluation cycle through a quantitative survey. Last, we
discuss our results and limitations as well as introduce
the further course of our study.

2. Theoretical background
2.1 Personalized healthcare
Tailoring services towards the individual is an
essential element of healthcare delivery [7]. Various
concepts address how to do this, such as personalized
medicine, person-centered care, and shared decisionmaking. Personalized medicine “encompasses the
application of genomic and molecular data to target
better the delivery of healthcare and more holistic
lifelong approaches.” [8, p. 208]. However, Di Paolo et
al. (2017) discovered that most personalized medicine
literature focuses on tailoring treatments to patients’
diseases without considering patients’ needs, beliefs,
behavior, values, wishes, utilities, environment, and
circumstances [7]. Patient preferences were hardly
considered when evaluating new medicines rather than
focusing on the stratification according to individual
biological information. As a response to that, personcentered care focuses on the person as a whole and is
responsive towards the person’s individual needs and
preferences [9]. To achieve person-centered care,
mutual involvement, and collaboration of the healthcare
professional with the patient are required [10]. This
collaboration process is referred to as shared decisionmaking. Shared decision-making is “an approach where
clinicians and patients share the best available evidence
when faced with the task of making decisions, and
where patients are supported to consider options, to
achieve informed preferences” [10, p. 1361]).

2.2 Explainable recommender systems in
healthcare
Recommender systems are tools to provide users
with suggestions for action [11]. With the digitalization
in almost all areas of daily life and the resulting increase
in data volume and complexity, these systems assist
users in dealing with this through condensing relevant
information to generated recommendations. This is also
evident in the healthcare industry [12]. To develop
recommender systems, three different techniques are
typically used [11].
(1) Collaborative filtering is the process of clustering
people with similar usage profiles. Likewise, this
approach can be applied across similar application areas
[13]. (2) Knowledge-based filtering uses existing
knowledge about the user, such as demographics [11].
(3) Content-based filtering compares different products
that the user has already used to estimate their similarity
and propose new products accordingly [14].
Nevertheless, the implementation of only one of these
solutions can lead to the so-called "cold start problem".
Due to an information gap, the recommender system
cannot develop a precise recommendation [15].
Therefore, the use of hybrid recommender systems is a
frequently used approach. Within these systems, at least
two decision strategies are combined to identify
recommendations [16].
To process a large amount of data through the
recommender system, various artificial intelligence (AI)
methods are used in healthcare today [13]. These
approaches mostly suggest a recommendation similar to
collaborative filtering but in a more precise manner [17].
AI refers, besides others, to the concept of machine
learning (ML) and deep learning (DL). These models
are trained in a data-driven way using mathematical
procedures without explicit programming [18].
Simultaneously, several problems are associated
with these AI-methods. One main problem is the
complexity of the generated models resulting in blackbox models [19]. This black box model is not traceable
and, therefore, leads to trust issues. Consequently, this
lack of trust reduces the acceptance and willingness to
use such a recommender system [20]. The explainable
AI (XAI) research field attempts to address this issue
while preserving AI's benefits [21]. As trust is a core
element in healthcare, explainability is a frequently
targeted goal for AI systems in healthcare research [22].

3. Methodology
Our study aims to support women diagnosed with
CVD in their medical treatment decision-making
process. Specifically, this study reports on a first

Page 3839

iteration of the problem-centered approach to the Design
Science Research Methodology proposed by Peffers et
al. (2007) [23]. Further iterations will follow in
subsequent studies.
Identify problems & define objectives. We started
the first design cycle by investigating sex differences in
medical treatment and the under-representation of
females in clinical trials. Hereby, we regarded the needs
of female patients as well as the demands of healthcare
professionals within the treatment decision-making
process (e.g., [1], [24]). For this, relevant concepts were
identified to shape the solution space: For sociotechnical challenges faced through sex differences in
medical treatment, the concepts of shared decisionmaking (e.g., [10]) and person-centered care (e.g., [25],
[26]) were identified. For the technical perspective on
supporting shared-decision-making and personcentered care, explainable hybrid recommender systems
(e.g., [13], [27]) were chosen as a foundation.
Relevant literature is consulted and condensed to a
precise research gap and core findings to be considered
in the solution space based on a structured literature
review following the approach of Webster and Watson
(2002) [28]. We aim to find extant contributions dealing
with recommender systems in healthcare for shared
decision-making. We analyze the databases PubMed,
ScienceDirect, and Web of Science to find healthcarerelated
contributions.
Regarding
technical
contributions, we examine ACM Digital Library and
IEEE Xplore. For the field of business information
systems, AIS eLibrary is consulted. The following
search term pseudocode is used:
((health care | care) AND (shared decision-making |
patient-cent* | person-cent*) AND (gender equity |
gender disparity | gender differences | gender bias)
AND (recommend* system | decision support system)
AND (explainab* recommend* | artificial intelligence |
machine learning | deep learning | XAI))
Thereby, we were able to identify 5454
contributions. Through a meta-analysis, full-text
analysis as well as a forward and backward search, we
classify 46 contributions as relevant. The results are
presented in Chapter 4.
Design and development. To tackle sex differences
in medical treatment, this study proposes a reference
architecture as an artifact to support females in their
medical treatment decisions. Specifically, the identified
core concepts are used as a basis for a set of design
decisions regarding the required functionality of such an
artifact. These socio-technical design decisions are then
transferred into a set of technical design decisions
prescribing a possible implementation for the targeted
artifact. This reference architecture serves as a
foundation for implementing such an artifact in the

specific context of females with CVD sickness. The
results are presented in Chapter 5.
Evaluation. In this first iteration of the design cycle,
we evaluate the relevance of the problem space and the
basic idea of the reference architecture to generate datadriven female-specific recommendations on medical
treatment. The evaluation is conducted as a quantitative
survey with 43 German females at 35 years of age or
older, presented in Chapter 6.
Communication. In this first design cycle, we
propose a reference architecture as an artifact rooted in
extant research. The artifact can be considered an
exaptation contribution [29] as it tackles a new problem
with established concepts and solutions. With this first
iteration of the design cycle, we posit a research-inprogress paper that will eventually yield a nascent
design theory contributing design knowledge to general
healthcare IS and sex-sensitive IS. Future research will
build on these initial steps.

4. Literature review
The literature review aims to find extant
contributions dealing with recommender systems in
healthcare for shared decision-making to understand the
targeted gap better and identify reusable concepts.
Person-centered care and sex differences. Personcentered care benefits both the patient, e.g., through
enhanced knowledge, improved relationship with
providers, service experience and satisfaction, treatment
compliance and health outcomes, as well as the health
system, e.g., through cost-effective service delivery
[30]. Nevertheless, many patients, especially females,
do not experience person-centered care due to a lack of
insight into operationalizing person-centered care for
females [31]. One explanation is the lack of attention
paid to person-centered care in medical guidelines [30].
Multiple strategies are proposed to improve personcentered care for females, including patient-oriented
tools in guidelines. These tools can, for example,
include information about the condition, lifestyle
advice, psychological strategies, and strategies for
communicating with healthcare professionals.
An observational study by Meijers (2019) showed
that the application of shared decision-making in
practice increased between 2007 and 2015 [32]. Despite
this increase, the level of shared decision-making is still
limited and leaves room for improvement. Another
study using the same measurement instrument in cardiac
stress testing found no significant sex effect [33].
A system allowing patients to access their medical
records maintained by a healthcare facility supports
patients to have an active role in their care process [34].
Ideally, this system also allows patients to interact with
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their healthcare providers. Currently, the management
of chronic conditions often relies on face-to-face visits
and infrequent measurements [35]. This may cause a
delay when interventions are needed since patients tend
to wait until symptoms are acute. Late detection of
serious symptoms can lead to expensive healthcare
services, requiring hospitalization, emergency room
visits, and unplanned readmissions. Early detection of
deteriorating health is therefore needed to improve
health outcomes and manage healthcare costs. Mobile
health has shown to impact health-related behaviors,
allowing patient self-management of their health status.
An example of a mobile health app monitoring and
analyzing health data of persons with and without
chronic diseases, and automatically alerting care
support staff based on purpose-developed algorithms is
the one developed in the study by Petersen (2019). The
app has three functional areas: health data, personal
profile, and secure messaging. The health data was
recorded through a fitness tracker smartwatch and data
entered by the patients manually. The personal profile
involved information on the patient’s personal
preferences, health goals, and social data. This
information is useful for healthcare providers to deliver
person-centered care. Secure messaging was possible
24/7 with a healthcare professional. The pilot
demonstrated that persons with chronic conditions were
actively engaged for a longer time than persons without
chronic diseases. Besides, the pilot uncovered
substantial potentials for the reduction in care costs for
persons with chronic care conditions.
Recommender systems. The necessity of
recommender systems in healthcare is frequently
discussed in research. Contributions such as [36]
highlight the need to integrate shared decision-making
with interactive recommender systems as the most
appropriate way to raise patient awareness. Therefore,
their application can be found in various approaches
such as telehealth [37], chatbots [36], or mobile
applications [41]. These approaches are also used to
address different areas of healthcare, such as diets [38],
drug treatment [39], dementia [40], support for the
elderly [41], or chronic diseases [42]. The described
recommender systems mostly use a hybrid collaborative
filtering technique to overcome the cold start problem
[42]. According to these contributions, mobile
applications differentiate themselves from others by
their high flexibility and acceptance, enabling the
elicitation of sensor and fitness data as an additional
source of information [43].
Furthermore, the review also shows that until 2017,
different cluster algorithms were mainly used for the
prediction of recommender systems. Due to the high
computational complexity, these contributions also
introduce outsourcing to cloud services [44]. On the

other hand, recent contributions focus on more complex
algorithms such as DL or natural language processing
due to their high predictive power and are also used in
high-stakes areas like radiology. Therefore, those
recommendations can support physicians in the drafting
of reports [45]. Simultaneously, the examination of
recent studies in this field reveals the necessity of
traceability of the predictions. Especially in critical
areas such as cancer detection [36]. Even in the
preliminary contributions, this has already been
discussed by pointing out decision factors of neural
networks when recommending treatments [46].
Identified knowledge gap. The analysis proves the
necessity of paying attention to how to improve sex
equity and shared decision-making in medical practice.
Several strategies and solutions were highlighted. An
already established approach is the use of recommender
systems through the application of mHealth, based on
explainable AI. However, in the analysis, no
contributions could be identified dealing with the
development of IS for shared decision-making to tackle
the prevailing sex differences despite the frequently
discussed relevance of this gap [31]. Therefore, our
study aims to develop a reference architecture to support
further developments in this field.

5. Designing female-sensitive personalized
drug management
In this section, we propose a set of means-end
relations, i.e., appropriate means (M) to achieve ends
(E) associated with the problem domain [47]. Those are
derived from both technical and socio-technical causeeffect relations identified from the reviewed literature
and inferred from the core concepts. These means-end
relations guide not only the instantiation of the derived
reference architecture, shown in Fig. 1, in our specific
context but can also be reused for health-related IS in
general.

5.1. First design cycle
Socio-technical considerations. Our approach to
tackling the knowledge gap on sex differences in
medical treatment evolves around increased patient
participation. Therefore, the artifact must be designed to
facilitate ease of use as a determinant for increased
patient participation (e.g., [48]) (E1). Following our
objective to develop an application that allows for
female-centered care, as a specific manifestation of
person-centered care, the literature emphasizes that it is
vital to elicit and incorporate an individual's values and
preferences (e.g., [25]). Therefore, the artifact has to
provide a way to collect and store data about patient
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Figure 1. Reference architecture for female-sensitive drug management.

preferences (E2). With the aim of the artifact to enable
a shared decision-making process, the literature points
out the importance of sharing the best available
evidence when facing the task of making a decision
(e.g., [10]). Therefore, the artifact has to provide ways
to track different types of information, including personcentered data, user preferences, and data on overall
patient wellbeing, general healthcare-related data, and
female-specific healthcare-related data (E3).
To deliver ground for a justified discussion to yield
shared decision-making for medical treatment (e.g.,
[49]), the artifact has to provide a condensed account of
the input data (E4). This information has to be shared
with the patient to trigger shared decision-making and
the healthcare professionals as a common ground for
discussion [10] (E5). However, they require different
degrees of information. While healthcare professionals
need detailed explanation and reasoning, for example,
about drug interactions, patients may rather be
interested in whether and how their preferences can be
mapped to their treatment (e.g., [49]). Hence, the artifact
must display information with varying perspectives and
degrees of detail per stakeholder (E6). Lastly, the
general problem targeted by the artifact arises from the
shortage of female-specific health-related data.
Therefore, the artifact also shares the female-specific
data collected by the artifact with academic and industry

drug research (E7) to close the knowledge gap for sex
differences in medical treatment.
Technical considerations. To increase patient
participation, the artifact needs to be flexibly available
to the patient anywhere, at any time [48]. Therefore, a
mobile application was chosen as the appropriate
interface for the patients (M1a). Moreover, ease of use
is facilitated through functionalities, such as taking a
picture of a medication instead of an interface requiring
long and tiring inputs by the user [50] (M1b).
User preferences can be elicited by incorporating a
patient survey. For the design of the survey, we follow
extant work (e.g., [51]) (M2). To achieve M2, extant
solutions incorporate various types of data. First,
general healthcare-related data can contribute to the
overall understanding of the interplay of drugs,
symptoms, and side effects, either specific for CVD or
general and either female-specific or sex-independent
data as proposed by the literature stream on evidencebased medicine (e.g., [52]). This data can be made
available to the artifact by establishing links to
renowned healthcare-related databases, such as
PharmacoGenomic Mutation Database (PGMD) [53]
and the Medscape Interaction Checker [54]. Therefore,
the artifact must provide linkages to healthcare-related
databases (M3a). Second, extant solutions elicit personcentered data directly related to the sickness, such as
monitoring drug intakes and data about the general well-
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being. Extant research frequently refers to this as
‘patient profiling’, including any information about
activities and the progression of symptoms and sideeffects over time (e.g., [55]). Therefore, the artifact
needs to provide users functionality to enter and track
all data related to their patient profile (M3b). Moreover,
Gyrard et al. (2020) propose to enhance patient-centered
data with sensor data such as heart rates [13]. While this
is not in the scope of our artifact, it may be available in
other health-related applications. Other wellbeing and
health-related applications, such as Apple Health or
menstrual cycle calendars, may also collect insightful
information and can deliver it to the artifact’s
recommendation engine if appropriately connected
(e.g., [56], [52]). Therefore, the artifact should provide
touchpoints to connect other health- and wellbeingrelated applications via APIs to retrieve further relevant
data (M3c).
A highly frequented approach to condense
information
in
healthcare
is
to
provide
recommendations based on the observed data within
recommender systems (e.g., [39], [36]). Therefore, the
artifact must provide a recommendation engine to
condense all the observed data for the shared decisionmaking process (M4a). Initial recommender systems
primarily rely on one type of data (e.g.,
transaction/behavioral data) and use the collaborative
filtering method [57]. More advanced recommender
systems additionally incorporate rather static data, such
as preference profiles (e.g., [58], [59], [60]). For the
artifact at hand, the recommender system ought to
incorporate all the available data. Extant solutions
exemplify how to incorporate user preferences [12],
patient profiles (e.g., [55]), and external database (e.g.,
[52]). Therefore, the artifact should be designed as a
hybrid recommender system to incorporate
transactional data and user preferences (M4b). For
recommender systems, their applications range from
disease discovery [67] over suggestions for physical
activity [60] to actual therapeutic recommendations
[57], i.e., many types of recommendations are possible.
As a starting point, the artifact will provide
recommendations on drug interactions, preferencebased alternations of drug intakes, and for scheduling an
appointment with a healthcare professional in the case
of irregularities (M4c). For any of these
recommendations and any of the posited data sources,
both female- and patient-specific as well as general
health-related data, any recommender system faces the
‘cold start problem’ (e.g., [27], [16]). The hybrid
approach allows us to propose initial recommendations
based on a limited amount of data and then collect and
learn from data accrued over time. Accordingly, initial
recommendations may rely on sex-independent data and
as the database grows over time, recommendations can

become more tailored to female- and patient-specific
needs. Also, with the database growing over time, more
types of recommendations may be possible. A value can
be created with a large and continuously growing
database through so-called data network effects, where
the multi-sided exchange among individual users allows
to improve recommendations for each user [61].
Therefore, the artifact should stimulate the continuous
collection and recording of data to evolve the
recommendations continuously (M4d).
To achieve shared decision-making, the patient, who
is in full possession of the mobile application and the
data therein, can share information with the healthcare
professional. Therefore, a login for healthcare
professionals is provided in the artifact, where the
patient can choose to share data explicitly with the
healthcare professional (e.g., through using a QR code
mechanism), so that the data remains secure (e.g., [37])
(M5). Recommendations require an explanation to be
understood and followed by healthcare professionals
and patients. Therefore, explainability is a core issue for
any recommendation system in the healthcare context
[22]. This issue is, for example, addressed by Che et al.,
2015, who explain their DL-based mortality prediction
[62]. Therefore, the artifact must provide sufficient
explanations for each recommendation (M6a).
Explanations must be adapted to stakeholders [63]. At
the same time, a patient may be satisfied with a
recommendation and indicators for how their
preferences were considered and will be realized by a
recommendation, a healthcare professional demands
further details such as the specific interplay of
components of drugs. Therefore, the artifact must
provide different perspectives and granularities of
explanations for each recommendation (M6b).
Lastly, the artifact wants to contribute the collected
data such as female-specific symptoms, side-effects,
sickness progressions, to the drug research, both
academic and industry, to close the gap of sexdifferences in CVD treatment. Both storing and sharing
health-related data raises data security issues, which
must be addressed for the IS artefact to be viable.
Therefore, the artifact provides an API to retrieve fully
anonymized datasets from the backend (M7).

5.2. First evaluation cycle
In design science research, an evaluation is crucial
to demonstrate the utility, quality, and efficacy of a
proposed artifact [64]. While the designed reference
architecture followed socio-technical requirements and
was technically grounded on findings in extant research,
we evaluate and plan to evaluate further both the
relevance of the problem space as well as the suitability
of the proposed solution. In this first evaluation cycle,
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we conducted a quantitative survey to verify the
relevance of lacking sex-specific knowledge to females
and whether females would like to be empowered
through technology to better participate in their medical
treatment decision-making process.
Method. A quantitative online survey was
conducted from 19th to Jun. 25th, 20201. A pretest was
conducted to check for clarity and correct spelling of the
questions. The participants were reached via a recruiting
pool, receiving incentives, as well as by using snowball
sampling. Women of 35 years of age or higher were
included in this German study. We applied a 5-point
Likert scale (1 = strongly disagree, 5 = strongly agree).
In total, 45 participants completed the survey, from
which two low-effort responses were excluded from the
analysis due to non-varying scale options; therefore, the
sample group consists of 43 completed surveys.
Procedure. The survey opened with an introduction,
addressing the lack of knowledge on sex differences in
medical treatment. Along with eight questions,
respondents were asked for their interest in receiving
medical recommendations and their willingness to track
their medical condition, share their data for
recommendation processing, and forward personal
health data to healthcare professionals and drug
research. Also, their current use of health-related
applications was inquired.
Results. Eighty-four percent of the respondents
strongly agreed to wish to receive recommendations
regarding
drug
interactions,
preference-based
alternations of drug intakes, and - in case of
irregularities - to get in touch with a healthcare
professional (M = 4.76, SD = 0.55). This is in line with
previous research on technology-enhanced, personcentered care reporting that patients with chronic
conditions, such as CVD, are “more likely to remain
engaged” with the technology [35, p. 10]. Receiving
explanations in addition to the recommendation itself to
understand better the effects of one’s drug usage and
influencing factors was strongly wished for as well
(M = 4.67, SD = 0.64). Thirty percent neither agreed nor
disagreed with preferring a mobile application to collect
and store personal health data, preferences, diseasespecific data, and data on one’s overall well-being;
25.6% agreed (M = 3.00, SD = 1.24). Regarding data
sharing with healthcare professionals, 25.6% agreed and
44.2% strongly agreed (M = 3.93, SD = 1.23). Sharing
the data with academic and industrial research, was
37.2% agreed on and 30.2% strongly agreed on by
participants (M = 3.16, SD = 1.20). However,
participants would rather not share their data with the
recommender system for the sake of receiving more
precise drug recommendations or - in equal shares - are
1

regardless of that (30.2% each, M = 2.65, SD = 1.27).
More than half of the participants already use a fitness
app to track activities such as running or biking (55.8%).
A calendar app for the menstrual cycle is used by 23.3%.
The general perception of the respondents that sharing
personal health-related data can help overcome the lack
of sex equity in medical research was consensual (M =
3.44, SD = 1.06).
Implications. The survey showed that respondents
are willing to receive recommendations regarding their
drug management. They also demand explanations for
the provided recommendations and are willing to use the
information for engaging in shared decision-making
with their healthcare professionals. Also, they are
willing to give away their data for research purposes to
enhance female-specific medical treatment. However,
in contrast to the high motivation to participate in shared
decision-making for their medical treatment, they are
reluctant to receiving improved recommendations to
compensate for their data sharing. This implies that the
adoption of such technology and, thus, the data
collection, are more likely to succeed if users benefit
from using the app through concomitant outcomes, i.e.,
tracking their health-record and getting detailed
explanations on the observable data. Also, respondents
do not explicitly consider a mobile application the
preferred option to collect their health-related data.
However, this is contrary to the result that more than
half of the participants already use health-related mobile
applications. In sum, the study shows that there is a need
for female-sensitive, personalized recommendations
and explanations for which data-driven solutions with
female-specific design considerations are a promising
path. Further research on socio-technical requirements
is required to understand better female patient’s needs
as well as the utility of such applications in the daily
routines of women to deduct specific sex-related
requirements for the design of the proposed artefact.

6. Discussion
In this research-in-progress paper, we investigated
design considerations for technology-enhanced femalesensitive decision-making regarding CVD's medical
treatment. The result is a reference architecture with a
mobile application as the interface to patients and
healthcare professionals as well as a data-driven
backend to collect and process data on sex differences
in the medical treatment of CVD.

See https://doi.org/10.13140/RG.2.2.27950.54086

Page 3844

6.1 Contributions to theory and practice
From a theoretical perspective, there is a lack of
knowledge on handling sex inequity in healthcare
occurring through the underrepresentation of females in
clinical trials. Our study aims to close this gap in three
ways. First, we apply the concept of person-centered
care with the aim of closely monitoring the body
condition of each female patient to make data available
on female-specific side effects, course of a disease, and
general wellbeing under medication. Second, we apply
the concept of shared decision-making to enable females
to be more involved in their medical treatment decision
despite the lack of research knowledge on femalespecificity. Third, we apply the technical concept of
hybrid explainable recommender systems to realize
female-sensitive drug management along with the
concepts of person-centered care and shared decisionmaking to incorporate sex-differences in medical
treatment.
From a practical view, the implementation of the
reference architecture will serve female patients,
healthcare professionals, and drug researchers. First,
female patients are yet frequently not aware of sex
inequity in clinical trials and what this implies for their
medical treatment. Based on the mobile application, as
the patient interface in the reference architecture, female
patients can better understand how their preferences and
body specificity can be considered in their medical
treatment decision. Second, healthcare professionals
benefit from the condensed data made available to them,
primarily through the provided explanations, to allow
them to make better-tailored treatment decisions for
female patients. Third, the underrepresentation of
females in clinical trials can be tackled through the rich
records of female patient data accrued through the
mobile application. With females accurately tracking
their health-related data for their personal treatment
decision, drug research can be pointed towards relevant
areas of study to facilitate targeted investigation of
female-specificity in drug research and, ultimately, to
reduce the gap of female-specific knowledge for
medical treatments.

6.2 Future research
For the further progression of this study, we plan to
iterate further design cycles. The evaluation of our
current research state yielded essential feedback for the
next design phase. We currently develop and evaluate
mock-ups as a second design cycle that allows us to get
intermediate
patient
feedback
between
the
conceptualization and implementation. Having finished
the conceptualization, the data structure will be derived
and defined based on relevant data, both from

underlying drug management data sources and userrelated data, which are integrated into the
recommendation engine. Subsequently, we plan to
realize a first implementation of the artifact. Thereby,
we can build up an essential user base and basic
functionality such as data collection and
recommendations based on existing medical interaction
databases. Hereupon, the user base grows, and more
female-specific health data becomes available, allowing
to infer female-specific knowledge.
Based on these two upcoming design cycles, we seek
to evaluate further aspects: The architecture feasibility
will be verified through the actual implementation and
functional software testing for each component, the user
interface, and the recommendation engine. The sociotechnical requirements will be evaluated through
explorative (female) focus groups to identify concrete
sex-related requirements for the design of the proposed
artefact to appropriately address the specific needs of
the target group, the female patients, for a proper
interaction with the application. The utility of
recommendations will be assessed through in-app
feedback and documented changes in patient healthrelated data once recommendations were followed. Last,
the usability of the user interface will be monitored
based on app usage metrics derived from the user’s
behavior in the mobile application.

6.3 Limitations
Our study is limited in multiple ways despite the yet
limited scope of a research in progress paper. First,
healthcare-related IS underlie strong legal regulations,
which are mostly country-specific. Therefore, the
artifact must eventually be aware of its location to
ensure legal compliance, e.g., regarding data protection
and privacy regulations in the applicable law. Second,
as the data collected from patients is intended to be used
in drug research as a pointer towards relevant areas of
study, the data collection needs to be safe against any
type of manipulation. Hence, future research needs to
target the security aspects of both the mobile application
as well as the recommendation engine. Third, this
architecture is limited to German users but is
prospectively generalizable to other countries, thereby
extending the user base to benefit from a larger number
of users for more stable results for the recommender
system. Fourth, this study is limited to CVD patients.
However, we posit that architecture can be transferred
to any sickness affected by female-specific body
conditions, such as depression and diabetes. Fifth, there
is still a lack of ready-to-use solutions for explainable
AI. Accordingly, research is needed to develop
individual explainable solutions for each specific
recommendation.
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